💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Darunavir Ethanolate

CHEMBL1201127 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
593.7 g/mol
LogP
—
Phase
4

The ethanolate crystal form of darunavir, an HIV protease inhibitor used in combination antiretroviral therapy for HIV infection. Co-administration with a pharmacokinetic booster such as ritonavir or cobicistat is required for adequate drug exposure.

Molekularmasse

593,7000 g/mol

TPSA

169,00 Ų

Therapeutische Bereiche

Infectious Disease Asthma Generalized Anxiety Disorder Insomnia Hyperlipidemia Obesity HIV/AIDS Hepatitis C Tuberculosis Cardiovascular Disease

Wirkmechanismus

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1.CCO

                

                

                
                

                    
InChI

                    
InChI=1S/C27H37N3O7S.C2H6O/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26;1-2-3/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32);3H,2H2,1H3/t22-,23-,24+,25-,26+;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H43N3O8S

                    

                    
                    

                        
HBD / HBA

                        
4 / 10

                    

                    
                    

                        
Rotierbare Bindungen

                        
12

                    

                    
                    
                    

                        
Schwere Atome

                        
41

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
The ethanolate crystal form of darunavir, an HIV protease inhibitor used in combination antiretroviral therapy for HIV infection. Co-administration with a pharmacokinetic booster such as ritonavir or cobicistat is required for adequate drug exposure.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Darunavir Ethanolate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201127.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 23725083.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.